小RNA
甲状旁腺癌
微泡
实时聚合酶链反应
外体
逆转录聚合酶链式反应
接收机工作特性
折叠变化
下调和上调
癌症研究
生物
分子生物学
医学
基因表达
癌
内科学
病理
基因
遗传学
作者
Jiacheng Wang,Qian Wang,Teng Zhao,Xing Liu,Ge Bai,Yunhui Xin,Hong Shen,Bojun Wei
出处
期刊:Endocrine
[Springer Science+Business Media]
日期:2020-11-08
卷期号:72 (1): 239-248
被引量:14
标识
DOI:10.1007/s12020-020-02535-7
摘要
The expression pattern of exosomal miRNAs derived from parathyroid tumor is still unknown. In the present work, we aimed to examine the differences on microRNA (miRNA) expression, present in serum exosomes, by comparing parathyroid carcinoma (PC) and parathyroid adenoma (PA). MiRNA expression profile of serum exosomes, derived from 4 PC patients and 4 PA patients, were analyzed by next-generation sequencing technology. The differential expressions of target miRNAs were further verified in both serum exosomes and tissues of PC/PA patients by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Lastly, receiver operating characteristic (ROC) curves were plotted to investigate the efficiency of target exosomal miRNAs in distinguishing PC patients from PA controls. Multiple differentially expressed miRNAs of serum exosomes were screened out by sequencing. Based on this screening, hsa-miR-146b-5p (p = 0.0846), hsa-miR-27a-5p (p = 0.0412), hsa-miR-93-5p (p = 0.73), hsa-miR-381-3p (p = 0.1239) and hsa-miR-134-5p (p = 0.0694) were upregulated in the serum exosomes of PC patients. These results were validated by qPCR, where the trend on differential miRNA expression was consistent with the sequencing results. Specifically, the expression of exosomal hsa-miR-27a-5p was able to clearly distinguish PC patients from PA controls, and related analysis indicated that the area under the ROC curve was 0.8594 (p = 0.0157). Here we present, for the first time, the miRNA expression profile of serum exosomes derived from PC patients. Based on this result, we presently suggest that the exosomal hsa-miR-27a-5p may serve as a putative tumor marker for preoperative identification of PC and PA subjects.
科研通智能强力驱动
Strongly Powered by AbleSci AI